Insights / October 16, 2019 / by beaconlbs

Featured Lab-Of-Choice: GeneDx

BeaconLBS has invited the Labs-of-Choice™ to provide some more information about themselves for a blog series featuring each of the Labs-of-Choice. The following content was provided by the featured lab, GeneDx.

Company Description: Rare Genetics Laboratory

GeneDx was founded in 2000 by two scientists from the National Institutes of Health (NIH) to diagnose patients with rare disorders and assist clinicians responsible for treating these patients. GeneDx has become a global industry leader in genetics and genomics, having provided testing to patients and their families in over 55 countries.

Led by its clinical genomics program, and a comprehensive genetic testing menu, GeneDx offers genetic testing for hereditary cancers, cardiac, mitochondrial, rare and neurological disorders, prenatal diagnostics, and targeted variant testing. To date, GeneDx has performed over 150,000 exomes. www.genedx.com

You Might Also Like:

Insights / August 27, 2018 / by beaconlbs

Beacon LBS Lab Benefit Management Leads to Improved Evidence Based Care and Lower Costs

Modern point of care lab benefit management is a must for payers, hospitals and other health systems. Learn how BeaconLBS solutions can point healthcare providers to evidence based solutions and reduce lab costs.

Global Lab Testing / January 14, 2019 / by beaconlbs

Making Sense of Prostate-Specific Antigen (PSA) Testing

Confusion exists the role of routine PSA testing in screening for prostate cancer. BeaconLBS answers your questions below in our blog about the history, role and evidence regarding routine PSA testing.